Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated, Aggressive B-cell Lymphoma

X
Trial Profile

A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated, Aggressive B-cell Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golcadomide (Primary) ; Iberdomide (Primary) ; Polatuzumab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Prednisone; Rituximab; Rituximab; Vincristine
  • Indications B-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results (n=78) assessing combined results from the GOLCA dose escalation and expansion phases, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 11 Dec 2023 According to a Bristol-Myers Squibb media release, data from this study being presented at the 2023 American Society of Hematology (ASH) Annual Meeting from December 9-12.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top